Primorigen Biosciences has been acquired by Nucleus Biologics, a leader in precision cell culture, the company announced today.

“The exceptionally strong fit of the Nucleus and Primorigen product portfolios provide a compelling value proposition for customers seeking more complete solutions for cell biology research and production,” Primorigen CEO Chuck Oehler said in a statement.

According to a release, the addition of Primorigen’s Vitronectin XF and platform recombinant protein production technology will play a role in Nucleus’ strategy of offering traceable, reproducible and xeno-free cell culture ecosystems for the cell and gene therapy space.

Financial terms of the deal were not disclosed.